RVRC · CIK 0001839140
REVIUM Rx.
Annual figures as reported, FY2024–FY2025. Ratios and growth rates derived on-page.
Pharmaceutical Preparations
Company profile
Net income
−$13.4M
Diluted EPS
−$0.22
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Key ratios
derived per fiscal year| Fiscal year | ROE | ROA | Current ratio |
|---|---|---|---|
| FY2025 | −195.5% | −162.1% | 2.26× |
| FY2024 | — | — | 9.58× |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 | — | — | — | −$13.4M | −$0.22 | — | — | $8.3M | $1.4M | $6.9M | $1.7M | — |
| FY2024 | — | — | — | — | — | — | — | $20.3M | $576K | $19.7M | $3.3M | — |
Latest filings
the most recent regulatory filings8-KCURRENT REPORT2026-06-22 ↗8-KCURRENT REPORT2026-06-01 ↗10-QQUARTERLY REPORT2026-05-14 ↗8-KCURRENT REPORT2026-04-20 ↗10-KANNUAL REPORT2026-03-31 ↗EFFECTSEC filing2026-01-30 ↗S-1/AAMENDMENT NO. 5 TO FORM S-12026-01-28 ↗S-1/AAMENDMENT NO. 4 TO FORM S-12026-01-16 ↗S-1/AAMENDMENT NO. 3 TO FORM S-12025-12-12 ↗S-1/AAMENDMENT NO. 2 TO FORM S-12025-10-03 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.